SCHEDULE 13G/A: T. Rowe Price Discloses 6.5% Stake in Quest Diagnostics

T. Rowe Price Associates, Inc. has reported a 6.5% beneficial ownership stake in Quest Diagnostics Inc. as of June 30, 2025.

Summary

• T. Rowe Price Associates, Inc. is the reporting person for this Schedule 13G filing.
• The filing indicates beneficial ownership of 7,209,622 shares of Quest Diagnostics Inc. common stock.
• This ownership represents 6.5% of the class of securities.
• T. Rowe Price Associates, Inc. holds sole voting power over 7,006,583 shares.
• T. Rowe Price Associates, Inc. holds sole dispositive power over 7,194,697 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of beneficial ownership by a major institutional investor, indicating a stable, significant holding. It does not contain performance data or forward-looking statements that would significantly alter sentiment, but a large institutional stake is generally a neutral to slightly positive signal.

Future Outlook

This filing does not contain forward-looking statements or guidance from Quest Diagnostics Inc. or T. Rowe Price Associates, Inc. regarding the issuer's future performance.

Industry Context

The disclosure of a significant stake by a major investment adviser like T. Rowe Price in a healthcare diagnostics leader such as Quest Diagnostics indicates continued institutional interest in the sector, often reflecting confidence in the company's market position and long-term prospects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and trading activity.

Key Dates

Keywords

Quest Diagnostics, T. Rowe Price, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Investment Adviser